Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies
Qinyu Ni, Lixin Rui · 2026
Read Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies by Qinyu Ni, Lixin Rui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13382581.txt.
Description
Qinyu Ni and Lixin Rui wrote a 2026 review of why cancers of B cells stop responding to a class of targeted drugs called BTK inhibitors. These drugs transformed care for several blood cancers, including chronic lymphocytic leukaemia and mantle cell lymphoma, after the first arrived a decade ago. Resistance is now a major challenge.
The review organises resistance into several routes. They include gene mutations in the drug's target and backup signalling pathways switching on. Altered protein levels, changes in the tissue around the tumour, and shifts in energy use also play a part. It then surveys counter-strategies in testing, from newer reversible inhibitors and targeted protein degraders to combinations with other modern therapies.
Catalog record
| CREATOR | Qinyu Ni, Lixin Rui |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76613 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |